Consolidated Balance Sheets - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 2,202,000	$ 5,711,000
Accounts receivable, net	15,000	25,000
Prepaid expenses and other current assets	343,000	619,000
Total current assets	2,560,000	6,355,000
Property and equipment, net	982,000	1,072,000
In process research and development	10,461,000	10,461,000
Acquired patents, net	299,000	307,000
Total assets	14,302,000	18,195,000
Current liabilities
Accounts payable and accrued expenses	1,109,000	1,659,000
Deferred revenue	86,000
Accrued compensation	884,000	895,000
Dividends payable	38,000	38,000
Insurance premium liability	161,000	185,000
Note payable	598,000	803,000
Total current liabilities	2,876,000	3,580,000
Derivative liabilities	2,329,000	2,443,000
Deferred tax liability	2,449,000	2,449,000
Total liabilities	7,654,000	8,472,000
Series B redeemable convertible preferred stock
$0.01 par value; 9,357,935 shares authorized at March 31, 2017 and December 31, 2016; no shares issued and outstanding at March 31, 2017 and December 31, 2016
Stockholders' equity
Common stock, $0.01 par value; 67,000,000 shares authorized at March 31, 2017 and December 31, 2016; 1,648,751 shares issued and outstanding at March 31, 2017 and December 31, 2016	165,000	165,000
Additional paid-in capital	391,097,000	390,918,000
Accumulated deficit	(384,614,000)	(381,360,000)
Total stockholders' equity (deficit)	6,648,000	9,723,000
Total liabilities, Series B redeemable convertible preferred stock and stockholders' equity	$ 14,302,000	$ 18,195,000